奥库利斯制药

最新新闻

• 评级变动
  BofA Securities Maintains Oculis(OCS.US) With Buy Rating, Cuts Target Price to $35
  \u5e02\u573a\u8d44\u8baf · 2026/6/1
• Top-performing Hong Kong stocks this week | Lightelligence shares rose more than 21% for the week, with its Scale-up OCS becoming a core growth engine; the company was included in the Stock Connect program this month. Maifeishi gained nearly 21%, upgradin
  \u5e02\u573a\u8d44\u8baf · 2026/9/5
• 评级变动
  LifeSci Capital Maintains Oculis(OCS.US) With Buy Rating, Cuts Target Price to $41
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• Stifel Maintains Oculis(OCS.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 评级变动
  Guggenheim Maintains Oculis(OCS.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 公司公告
  Trendlines: General Announcement-OCS Expands Mandate of Trendlines Medical - Misgav Ltd. to include Agtech Investments
  SGX · 2016/6/21
• 公司公告
  Trendlines: General Announcement-OCS Definitive Approval on Expansion of the Mandate of Trendlines Medical - Misgav Ltd.
  SGX · 2016/10/11
• 评级变动
  LifeSci Capital Maintains Oculis(OCS.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• H.C. Wainwright Maintains Oculis(OCS.US) With Buy Rating, Maintains Target Price $26
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• Dongtu Technology (300353.SZ): The industrial network communications business segment does not involve OCS optical circuit switching products.
  Gelonghui Finance · 2026/9/23
• 评级变动
  TransMedics (TMDX): Buy Rating Backed by Accelerating U.S. Organ Transplant Volumes and Expanding OCS Utilization
  TipRanks · 2026/8/3
• 评级变动
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Oculis Holding (OCS), Stevanato Group (STVN) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)
  TipRanks · 2026/8/10
• 评级变动
  Decolite (688205): DCI volume is surging at the right time, and OCS deployment is laying the groundwork for a competitive edge.
  AVIC Securities · 2026/6/16
• H.C. Wainwright Maintains Oculis(OCS.US) With Buy Rating, Raises Target Price to $39
  \u5e02\u573a\u8d44\u8baf · 2026/9/18
• 评级变动
  J.P. Morgan Maintains Oculis(OCS.US) With Buy Rating, Announces Target Price $23
  \u5e02\u573a\u8d44\u8baf · 2026/6/3
• 评级变动
  LifeSci Capital Maintains Oculis(OCS.US) With Buy Rating, Maintains Target Price $41
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• 评级变动
  Baird Maintains Oculis(OCS.US) With Buy Rating, Cuts Target Price to $38
  \u5e02\u573a\u8d44\u8baf · 2026/6/2
• 评级变动
  J.P. Morgan Maintains Oculis(OCS.US) With Buy Rating, Cuts Target Price to $20
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  Needham Maintains Oculis(OCS.US) With Buy Rating, Maintains Target Price $38
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• 评级变动
  J.P. Morgan Gives a Buy Rating to Oculis Holding (OCS)
  TipRanks · 2026/8/14

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。